Ainos Reports First Quarter 2024 Financial Results
Accesswire
*Strategic focus on VELDONA and AI-powered point-of-care testing continues during 2024*
*US$9M growth capital secured in..
*Strategic focus on VELDONA and AI-powered point-of-care testing continues during 2024*
*US$9M growth capital secured in..
*Strategic pivot towards VELDONA and AI-powered point-of-care testing to continue in 2024*
*Advancing VELDONA drug..
*Bona Fide Masks Expands Role as The Trusted Source*
*RYE, NY / ACCESSWIRE / February 1, 2024 / *Bona Fide Masks Corp...